BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Bruker Corporation. (5/29/09). "Press Release: Bruker Daltonics Announces Schering-Plough’s Selection of the New solariX FTMS for Structure Characterization and Impurity Testing". Billerica, MA.

Organisations Organisation Bruker Daltonics (Operating Business of Bruker Corporation)
  Group Bruker Corporation (Group)
  Organisation 2 Schering-Plough Research Institute (SPRI)
  Group Merck (US) (Group)
Products Product solariX™ FTMS platform
  Product 2 NMR spectroscopy
Persons Person Martin, Gary (Schering-Plough 200905 Leader RSCL at SPRI)
  Person 2 Speir, Paul (Bruker 200905 VP FTMS Bruker Daltonics)

Bruker Daltonics announced today that the Rapid Structure Characterization Laboratory (RSCL) of the Schering-Plough Research Institute (SPRI) has selected the new solariX™ FTMS platform from Bruker Daltonics as a cutting-edge tool for structural characterization and purity assessment of pharmaceuticals under development at SPRI. The solariX, with its expansive capabilities, is ideally suited as the ultimate analysis platform to address the rigorous challenges of these application areas in pharmaceutical development.

Bruker Daltonics explained that the RSCL can be tasked with solving some of the most difficult chemical structure problems encountered during drug development, as well as many day-to-day applications, that companies have for structural characterization of chemical compounds.

Dr. Gary Martin, Distinguished Fellow at Schering Plough and the leader of the RSCL, commented: "The chemical formula provided by the solariX platform for both the complete unknown, as well as pieces of the unknown compound from MSn, is pivotal information that can complement the information derived from NMR spectroscopy. Combining these data can speed the solving of complex structural problems. We look forward to using solariX in our work."

Dr. Paul Speir, Vice President for FTMS at Bruker Daltonics, stated: "Our solariX FTMS platform offers unmatched mass resolution and flexibility, a wide variety of ionization techniques, the capability to perform MSn experiments with accurate mass measurement at each stage, and is even capable of ion-molecule reactions. All of these capabilities can be useful in solving the extremely difficult structural characterization problems that pharmaceutical scientists routinely encounter."

For further product information, please visit


For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit and

Bruker Daltonics
Dr. Paul Speir, +1 978-663-3660

Record changed: 2016-03-19


Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Bruker Corporation (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px